| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 181.20 | 12.0% | 3.8% |
| Total Income | 184.97 | 12.0% | 0.7% |
| Expenditure | 165.20 | 7.5% | 4.4% |
| PBT | 19.77 | 37.4% | 22.4% |
| Net Profit | 15.25 | 36.3% | 21.5% |
| OPM | 25.63% | 3.09pp | 32.85pp |
| NPM | 8.24% | 3.15pp | 2.33pp |
| EPS | 4.72 | 36.0% | 21.5% |
Krsnaa Diagnostics: Operationally Resilient Quarter with Seasonal Revenue Softness; Rajasthan Rollout to Drive Revenue Growth from Next Year
05 Feb 2026 · 5 Feb, 7:19 pm
Summary
Krsnaa Diagnostics Ltd. is one of India’s fastest-growing integrated diagnostic service providers. The Company today announced the results for the Nine months & Quarter ending December 31, 2025. Financial Performance 9MFY2026 Revenue 3 5,802 mn 9% YoY t EBITDA % 1,600 mn 13% YoY PAT=597mn5% YoY tt Financial Overview Q3 FY2026: Y-o-Y (Rs. Million) Q3FY26 | Q3FY25 Grows Q2FY26 Q-o-QGrowth|) 9MFY26 QMFY25 __s Y-0-Y Growth REVENUE from’) 4g12 | 1,745 4% 2,060 (12%) 5,802 5,311 9% Operations Other Income 38 92 42 119 211 Total Income 1,850 | 1,837 1% 2,102 (12%) 5,921 5,522 7% EBITDA! 474 466 2% 602 (21%) 1,600 1,416 13% Margin % 26% 27% 29% 28% 27% EBIT! 285 331 (14%) 408 (30%) 1,040 964 8% Margin % 15% 18% | 19% 18% 17% Profit After Tax 152 194 (21%) 239 (36%) 597 569 5% Margin % 8% 11% 12% 10% 11% reponse’ Diluted! 4.66 5.88 7.25 18.16 17.26 Normalized 484 466 4% 602 (20%) 1,610 1,416 14% EBITDA Margin % 27% 27% 29% 28% 27% Normalized EBIT2 295 283 4% 408 (28%) 1,051 916 15% Margin % 16% 15% 19% 18% 17% pean Profit 168 169 (1%) 247 (32%) 628 567 11% Margin % 9% 10% 12% 11% 11% Notes: 1. EBITDA excludes CSR and ESOP, and EBIT including Other Income 2. Normalized EBITDA excludes CSR, ESOP, and operational expenses incurred due to the ongoing implementation of the Rajasthan pathology project and the change in labour law aggregating Rs.10 mn. wherein revenue is not proportionate to these expenses. Normalized PAT excludes the above-mentioned expenses. Financial results of the Company are best monitored on annual basis, as there is a certain level of cyclicity in business and specific quarter performance may be impacted by specific events in that quarter
Key Highlights
- 1
9% YoY growth in revenue for 9MFY2026
- 2
13% YoY growth in EBITDA for 9MFY2026
- 3
5% YoY growth in PAT for 9MFY2026
- 4
7% YoY growth in total income for Q3FY2026
- 5
2% QoQ growth in EBITDA for Q3FY2026
- 6
8% QoQ growth in profit for Q3FY2026
- 7
Cash recoveries of over 3130 crore during Q3
- 8
Launch of the first hospital under Apulki Healthcare
Management Comments
Mr. Yash Mutha
Managing Director
Q3 is traditionally a seasonally softer quarter for the diagnostics industry, but what stands out this quarter is the strength of execution beneath the numbers. During the quarter, we undertook focused and disciplined actions to improve working capital efficiency and accelerate recovery of long-pending government receivables. These measures resulted in cash recoveries of over 3130 crore during Q3. Importantly, cash recovered during the quarter was over 2100 crore higher on a year-on-year basis compared to the corresponding quarter last year, reflecting a structurally stronger collections framework and improved maturity of our operating model. EBITDA margins during the quarter reflect deliberate, front-loaded investments to support the next phase of growth, particularly the rollout of India’s largest pathology PPP initiative — the Rajasthan Pathology Project. While certain manpower and readiness costs have been incurred ahead of revenue generation, the project is progressing fully as planned, with meaningful revenue commensuration expected from the next financial year. Encouragingly, our B2C segment continues to build strong momentum, recording multi-fold growth during the quarter. We are seeing steadily rising acceptance of the Krsnaa brand in the consumer market, driven by our focus on high-quality diagnostics, round-the-clock service availability, and pricing that remains meaningfully more affordable than regional alternatives. As brand trust deepens and our specialty portfolio expands, this segment is emerging as a meaningful contributor to sustainable growth, profitability, and long-term shareholder value.
Ms. Pallavi Bhatevara
Executive Director
At Krsnaa Diagnostics, we remain deeply committed to delivering high-quality, accessible, and patient-centric diagnostic services, underpinned by strong governance, integrity, and operational excellence. Through our differentiated Public-Private Partnership (PPP) model, we have successfully built one of India’s largest platforms for providing free and affordable diagnostic services, enabling millions of patients across the country to access essential healthcare. Our expanding pan-India footprint and long-standing collaborations with multiple state governments have firmly positioned Krsnaa Diagnostics as a trusted, preferred, and scalable partner in India’s public healthcare ecosystem, with strong execution credibility and long- term growth visibility. We are pleased to announce the launch of the first hospital under Apulki Healthcare, marking a significant strategic milestone as we extend our capabilities beyond diagnostics into integrated tertiary care. Apulki’s flagship project in Pune, developed in partnership with the Pune Municipal Corporation, is India’s first PPP-based cancer and cardiac hospital, reinforcing our leadership in executing complex, high-impact public healthcare infrastructure projects. The 150-bed facility
Informational and educational content only. Not investment advice.